BREVAGenplus is designed to enable more informed decision-making. A Personalized Preventive Breast Health Treatment Plan can then be developed for high-risk patients.
Management plans may include:
- Pharmacologic Risk Reduction
- Some medications may potentially prevent cancer in approximately 50% of women who are identified at
- Lifestyle changes
- Increased clinical encounters
- Annual mammogram or tomosynthesis screening
We recommend that if your patient comes back at increased risk, that you refer her out to a breast cancer prevention specialist for follow-up. At the follow-up visit, your patient will likely undergo a more scrutinizing set of clinical questions to address additional risk factors associated with breast cancer. Following that thorough clinical assessment, risk reduction options will be presented to her that are personalized to her current health status and lifestyle goals. If your patient choses risk reduction medications and has an intact uterus, she may require a baseline gynecological assessment1. Depending on the risk reducing medication chosen for her medical management plan, she may require ophthalmologic evaluation2, bone mineral density scan3 or monitoring for symptoms of deep vein thrombosis or pulmonary emboli4.
- BREVAGenplus™ provides information about breast cancer risk over a 5 year period; it does not diagnose breast cancer
- BREVAGenplus is validated in African American, Caucasian, and Hispanic women age 35 years or older
- The risk estimate used in this test does not take into account several other breast cancer risk factors, such as an extensive family history of breast and ovarian cancer and thus does not provide a lifetime risk score
- This test is used for clinical purposes
* BREVAGenplus is not applicable to women who are already at high risk of breast cancer including those that have a personal or extensive family history of breast and/or ovarian cancer, LCIS, DCIS, AH or have thoracic RT under 30y. Any women with these risk factors are already at increased risk of breast cancer and should be screened and followed as such.
1. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006;107:1475-1478
2. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
3. P. Hadji, J. -J. Body, M. S. Aapro, A. Brufsky et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol (2008) 19 (8): 1407-1416.
4. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-947.